EGFR and breast carcinoma: Among these compounds, compound 25 has a promising potency for VEGFR2 and EGFR (IC50 = 19.8 nM and 11.4 nM, respectively), and stronger antitumor effects on human breast cancer cell lines MCF-7 compared with that of molecule 1 and EGFR inhibitor erlotinib.